All In Biotech

Drug Trial Radar · NCT06178367

Effectiveness and Safety of Topical Hyaluronic Acid of Different Molecular Weights in Xerotic Skin Treatment

Effectiveness and Safety Comparison Between Moisturizers Containing Low Molecular Weight Hyaluronic Acid, High Molecular Weight Hyaluronic Acid, and Vehicle on Skin Hydration in the Elderly With Xerotic Skin

Last checked: Nov 20, 2026Latest source record: Apr 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

36

Actual

Start

Aug 26, 2023

Primary completion

Sep 30, 2023

Study completion Sep 30, 2023

Sponsor

Lead sponsor
Universitas IndonesiaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 60 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to compare 0,1% topical low molecular weight (7 kDa) hyaluronic acid with 0,1% high molecular weight (1.800 kDa) hyaluronic acid as therapy of xerotic skin in elderly

Conditions

  • Xerosis Cutis

Interventions

  • Low molecular weight hyaluronic acidDrug

    Topical 0,1% low molecular weight (7 kDa) hyaluronic acid in vehicle

  • High molecular weight hyaluronic acidDrug

    Topical 0,1% high molecular weight (1.800 kDa) hyaluronic acid in vehicle

  • VehicleDrug

    Vehicle ingredients including aqua, paraffinum liquidum, glycerin, petrolatum, hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer, arachidyl alcohol, squalane, behenyl alcohol, phenoxyethanol, arachidyl glucoside, allantoin, chlorphenesin, and disodium EDTA

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Skin capacitanceTime frame: 2 weeks and 4 weeks
  2. Transepidermal water lossTime frame: 2 weeks and 4 weeks
  3. Specified symptom sum score/scale, roughness, redness, crack (SRRC)Time frame: 2 weeks and 4 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Panti Sosial Tresna Werdha Budi Mulia 3

    Jakarta, DKI Jakarta, Indonesia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.